Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 2/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1979601 | 0.85 | SCN9A (0.46) | SCN9AFPR2HPGDSSYK | |
| SCHEMBL20567553 | 0.82 | MTNR1B (0.64) | MTNR1BPGRARSYK | |
| SCHEMBL21980916 | 0.80 | ACACB (0.38) | HTTHPGDS | |
| SCHEMBL1978265 | 0.80 | XIAP (0.58) | MTNR1BLTA4HGAAHTTPGR | |
| SCHEMBL13721712 | 0.79 | SMN1; SMN2 (0.43) | MTNR1BLTA4HGAAHTTSYK | |
| SCHEMBL13721111 | 0.78 | SCN9A (0.46) | SCN9AFPR2LTA4HGAAHPGDS | |
| SCHEMBL1979299 | 0.78 | MTNR1B (0.52) | MTNR1BGAAHTTPGRAR | |
| SCHEMBL13832459 | 0.75 | MTNR1B (0.52) | MTNR1BLTA4HHTT | |
| SCHEMBL29564854 | 0.74 | SYK (0.59) | MTNR1BSYK | |
| Hydrochloric Acid SCHEMBL29564676 | 0.72 | SYK (0.58) | MTNR1BSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885MTNR1B 1903/4885FPR2 4838/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | SCN9A 88/4885MTNR1B 1903/4885FPR2 4838/4885 |
| US-20200163964-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | SCN9A 88/4885MTNR1B 1903/4885FPR2 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.